AcelRx Pharmaceuticals Inc.

Trade-Ideas LLC identified AcelRx Pharmaceuticals (ACRX) as a weak on high relative volume candidate

Trade-Ideas LLC identified AcelRx Pharmaceuticals (ACRX) as a strong on high relative volume candidate

There's a valuable, albeit painful, lesson here in Amicus' blow-up. Biotech CEOs should shut their mouths about regulatory plans until they receive definitive word from the FDA.

These stocks look ready to break out and trade higher from current levels.

These under-$10 stocks are within range of triggering breakout trades.

Some biotech stocks way underperformed in this red-hot sector.

Stocks with insider trader activity include LAD, RSE and ACRX

Stocks with insider trader activity include STFC, ACRX and CSC

AcelRx shareholders were burned yet again when the company announced new clinical trials were required for its flagship drug. What's to come for this struggling biotech company?

Shares of AcelRx Pharmaceuticals (ACRX) are extending losses as Jefferies downgraded the company to 'hold' from 'buy.'

AcelRx Pharmaceuticals (ACRX) shares are down over 30% after the company announced a delay to the resubmitting of Zalviso's regulatory application due to increased FDA scrutiny.

AcelRx Pharmaceuticals was hit with an FDA rejection and is due to resubmit their drug this quarter; should investors stay away or is there an opportunity to be had?

These setups often produce monster moves higher in very short time frames.

AcelRx Pharmaceuticals (ACRX) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D.

AcelRx Pharmaceuticals (ACRX) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.

Shares of AcelRx Pharmaceuticals (ACRX) surged in late morning trading Tuesday after the company reported third-quarter results after the market close Monday that beat analysts' expectations.

Trade-Ideas LLC identified AcelRx Pharmaceuticals (ACRX) as a strong on high relative volume candidate

Shares of AcelRx Pharmaceuticals (ACRX) plummeted to a 52-week low of $5.27 on Friday after the company announced a delay in resubmitting Zalviso for FDA approval.

These biotech stocks trading for less than $10 a share are within range of triggering breakout trades.

We are exiting AcelRx Pharmaceuticals. Plus, an update on Energy Recovery.

We exited one position during a mixed week for the portfolio.

We made several trades last week as all the major domestic stock market indices moved lower for the five days.

Here's our current thinking on AcelRx Pharmaceuticals, Antares Pharma, CPI Aerostructures and Pareteum.

We added to one position last week as as the small-cap heavy Russell 2000 dipped.

With the market rebounding, the majority of our positions rose week over week.

We ditched one position and added to another last week as small-cap stocks trended higher.

Last week was a very strong one for many of our positions as the domestic market ended the first quarter on a high note.

We initiated one position and exited another during a tough week for small-cap stocks.

Is action required for AcelRx Pharmaceuticals and Energy Recovery?

With the small-cap heavy Russell 2000 leading the major market index pack last week, we saw a number of pronounced moves higher in the portfolio.

Another melt-up for the stock market, together with a late-Friday surge was a positive for several portfolio holdings.

We added one new position and doubled down on another during a very good week for the portfolio.

We added a position in Fitbit, scaled deeper into AcelRx Pharmaceuticals and improved our cost basis in Pitney Bowes.

AcelRx Pharma has really taken it on the chin of late.

Given the market pressures of last week, there was little room to hide as the gut punches continued to hit small-cap and technology stocks.

We are not adding to our AcelRx position on this weakness, despite believing in the underlying story, until we have more information.

While health care holdings may suffer, cannabis-related holdings should get a boost.

Here’s when we would consider adding to Aurora Cannabis.

The distressed retail chain files for Chapter 11 bankruptcy, facing macroeconomic headwinds.

Dr. Alan Baratz sits down with TheStreet to explain why Nvidia's CEO is "dead wrong" about quantum computing's future.

Here’s what could be next for AMD and its AI ambitions.